The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and Collaboration
Authors: Veda N. Giri, Matthew B. Yurgelun, Mark E. Robson
Journal: Annals of Internal Medicine (2017)

Ideas and Opinions19 December 2017The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and CollaborationVeda N. Giri, MD, Matthew B. Yurgelun, MD, and Mark E. Robson, MDVeda N. Giri, MDSidney Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, Pennsylvania (V.N.G.), Matthew B. Yurgelun, MDDana-Farber Cancer Institute, Harvard Medical School, and Brigham and Women's Hospital, Boston, Massachusetts (M.B.Y.), and Mark E. Robson, MDMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York (M.E.R.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-2512 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Traditionally, genetic testing for inherited cancer risk has been limited to germline analysis for specific hereditary cancer syndromes (HCSs), such as BRCA1/2 testing for suspected hereditary breast or ovarian cancer syndrome and DNA mismatch repair (MMR) gene testing for suspected Lynch syndrome. With increasing capability and affordability of next-generation sequencing technology, commercial laboratories now offer an array of multigene panels that can analyze many cancer susceptibility genes in parallel (1). Further, precision medicine efforts in oncology are uncovering inherited mutations when tumor (somatic) sequencing is performed to identify mutational drug targets, and germline alterations themselves are increasingly being considered as ...References1. Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014;12:1339-46. [PMID: 25190699] CrossrefMedlineGoogle Scholar2. Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2016;2:104-11. [PMID: 26556299] doi:10.1001/jamaoncol.2015.5208 CrossrefMedlineGoogle Scholar3. Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012;21:151-61. [PMID: 22134580] doi:10.1007/s10897-011-9462-x CrossrefMedlineGoogle Scholar4. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152-1158. [PMID: 28302823] doi:10.1126/science.aam7344 CrossrefMedlineGoogle Scholar5. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW; American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223-62; quiz 263. [PMID: 25645574] doi:10.1038/ajg.2014.435 CrossrefMedlineGoogle Scholar6. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073-2087.e3. [PMID: 20420947] doi:10.1053/j.gastro.2009.12.064 CrossrefMedlineGoogle Scholar7. Moline J, Mahdi H, Yang B, Biscotti C, Roma AA, Heald B, et al. Implementation of tumor testing for Lynch syndrome in endometrial cancers at a large academic medical center. Gynecol Oncol. 2013;130:121-6. [PMID: 23612316] doi:10.1016/j.ygyno.2013.04.022 CrossrefMedlineGoogle Scholar8. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-413. [PMID: 28596308] doi:10.1126/science.aan6733 CrossrefMedlineGoogle Scholar9. Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23:517-525. [PMID: 28288110] doi:10.1038/nm.4292 CrossrefMedlineGoogle Scholar10. Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318:825-835. [PMID: 28873162] doi:10.1001/jama.2017.11137 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Sidney Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, Pennsylvania (V.N.G.)Dana-Farber Cancer Institute, Harvard Medical School, and Brigham and Women's Hospital, Boston, Massachusetts (M.B.Y.)Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York (M.E.R.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2512.Corresponding Author: Veda N. Giri, MD, Director, Cancer Risk Assessment and Clinical Cancer Genetics, Sidney Kimmel Cancer Center, Thomas Jefferson University, 1025 Walnut Street, Suite 1015, Philadelphia, PA 19107; e-mail, Veda.[email protected]edu.Current Author Addresses: Dr. Giri: 1025 Walnut Street, Suite 1015, Philadelphia, PA 19107.Dr. Yurgelun: 450 Brookline Avenue, Dana 1126, Boston, MA 02461.Dr. Robson: 1275 York Avenue, New York, NY 10021.Author Contributions: Conception and design: V.N. Giri, M.B. Yurgelun, M.E. Robson.Drafting of the article: V.N. Giri, M.B. Yurgelun, M.E. Robson.Critical revision of the article for important intellectual content: V.N. Giri, M.B. Yurgelun, M.E. Robson.Final approval of the article: V.N. Giri, M.B. Yurgelun, M. Robson.This article was published at Annals.org on 31 October 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors 19 December 2017Volume 167, Issue 12Page: 884-885KeywordsCancer geneticsCancer screeningDNADNA sequencingGenetic counselingGenetic testingHereditary nonpolyposis colorectal cancerMMR vaccineMutationPathogens ePublished: 31 October 2017 Issue Published: 19 December 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...